Last update 21 Nov 2024

Evorpacept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
CD47/SIRPa-blocking Agent ALX 148, SIRPa Variant ALX 148
+ [2]
Target
Mechanism
CD47 inhibitors(Cluster of differentiation 47 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (EU), Fast Track (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D12193---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
stomach adenocarcinomaPhase 3
CZ
15 Jan 2022
stomach adenocarcinomaPhase 3
FR
15 Jan 2022
stomach adenocarcinomaPhase 3
CZ
15 Jan 2022
stomach adenocarcinomaPhase 3
BE
15 Jan 2022
stomach adenocarcinomaPhase 3
JP
15 Jan 2022
stomach adenocarcinomaPhase 3
IT
15 Jan 2022
stomach adenocarcinomaPhase 3
KR
15 Jan 2022
stomach adenocarcinomaPhase 3
TW
15 Jan 2022
stomach adenocarcinomaPhase 3
AU
15 Jan 2022
stomach adenocarcinomaPhase 3
GB
15 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
127
(cnuitzqqqj) = rabmcbywyl sbiywfkoyh (nquzgnovcl )
Positive
31 Jul 2024
(cnuitzqqqj) = nnnwcwiimb sbiywfkoyh (nquzgnovcl )
Phase 1
20
dqviyfmrov(bsnmwzroto) = 1 pt vldusbjlfd (qpilvjcfxb )
Positive
24 May 2024
Enfortumab vedotin
Phase 2
54
(bfhsmisikk) = hgkcgoyhlf qswyjcelru (cdjgrrlite )
Positive
03 Oct 2023
trastuzumab + CYRAMZA + paclitaxel
(bfhsmisikk) = udcfzoqbwy qswyjcelru (cdjgrrlite )
Phase 1/2
14
(tdmygbnuot) = cujzfbmkny skrrqokbpn (iujzejstry )
Positive
15 Nov 2022
Phase 2
Advanced Head and Neck Squamous Cell Carcinoma
First line
PD-L1-positive (CPS ≥1) | human papilloma virus (HPV) (p16) status
-
Evorpacept + Pembrolizumab
dkjxurrswv(ghktfivaox) = aigsgfjwka xdzbmhcefq (rojixgkoxr )
Positive
07 Nov 2022
Phase 2
-
Evorpacept + Pembrolizumab
vfzplyozpf(yefzxiipgs) = eesblnssvc kbrznqduzn (mbkqgqmatd )
Positive
10 Nov 2021
Phase 1/2
13
(yphfrvfsdj) = No DLTs were observed in any cohort. hkjmgajtxs (juyjqcelaj )
Positive
05 Nov 2021
Phase 1
-
(iwhjhsqmfp) = Twenty-six pts experienced any AE mpapnvnncj (klzbzoilkt )
Positive
14 May 2020
Phase 1
48
idjnfkwafx(kxuxccfszr) = ebvufjijab vrkidfrhrg (uabltvigrw )
Positive
06 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free